380,638 Shares in Certara, Inc. (NASDAQ:CERT) Bought by Kopion Asset Management LLC

Kopion Asset Management LLC bought a new stake in Certara, Inc. (NASDAQ:CERT - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 380,638 shares of the company's stock, valued at approximately $4,457,000. Certara accounts for about 3.2% of Kopion Asset Management LLC's holdings, making the stock its 15th largest position. Kopion Asset Management LLC owned 0.24% of Certara at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its stake in shares of Certara by 4.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,871 shares of the company's stock valued at $317,000 after buying an additional 975 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Certara by 1.6% during the first quarter. Russell Investments Group Ltd. now owns 77,753 shares of the company's stock worth $1,375,000 after purchasing an additional 1,191 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of Certara by 2.3% during the second quarter. Louisiana State Employees Retirement System now owns 54,200 shares of the company's stock worth $751,000 after purchasing an additional 1,200 shares during the period. Texas Permanent School Fund Corp grew its stake in shares of Certara by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 93,729 shares of the company's stock worth $1,676,000 after purchasing an additional 1,213 shares during the period. Finally, Blue Trust Inc. acquired a new stake in shares of Certara during the second quarter worth $26,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Stock Up 0.1 %

Shares of Certara stock traded up $0.01 during trading on Wednesday, reaching $11.22. The stock had a trading volume of 863,111 shares, compared to its average volume of 748,019. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -28.74, a P/E/G ratio of 5.40 and a beta of 1.49. The stock has a fifty day moving average price of $11.71 and a two-hundred day moving average price of $14.50. Certara, Inc. has a 52 week low of $10.35 and a 52 week high of $19.87. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). The firm had revenue of $93.31 million during the quarter, compared to the consensus estimate of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The business's revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 earnings per share. Sell-side analysts predict that Certara, Inc. will post 0.27 EPS for the current fiscal year.

Insider Activity

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Certara news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares of the company's stock, valued at $552,503.73. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Leif E. Pedersen sold 51,224 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now owns 99,704 shares of the company's stock, valued at approximately $1,125,658.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on CERT shares. UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price objective for the company in a research note on Friday, September 27th. KeyCorp decreased their price objective on Certara from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Thursday, July 11th. Barclays reduced their target price on Certara from $16.00 to $14.00 and set an "equal weight" rating on the stock in a report on Tuesday. JMP Securities reiterated a "market perform" rating on shares of Certara in a report on Wednesday, July 10th. Finally, Robert W. Baird reduced their target price on Certara from $19.00 to $18.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $17.08.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.